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Introduction
Epigenetic modulation has emerged as a promising strategy for the treatment of human diseases, particularly cancer.
Recently, a number of metal-based epigenetic modulators have been identified.
Metal complexes can target histones or epigenetic modification enzymes.
Many transition metal complexes have been used throughout history for the diagnosis and treatment of a wide variety of disorders [1] [2] [3] [4] [5] . The unique properties of transition metal complexes, such as their structural diversity, interesting photochemical and photophysical properties, and their ability to form specific interactions with biomolecules, make them versatile alternatives to organic small molecules for drug discovery [6] [7] [8] [9] [10] . Alternatively, metal complexes have also been used as functional scaffolds for the development of sensory probes [11] [12] [13] [14] [15] .
Structurally, metal complexes consist of a metal center surrounded by a number of organic or inorganic ligands via coordination bonds. Metal complexes can adopt a large range of structural
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A c c e p t e d M a n u s c r i p t 4 types, including octahedral or square-planar geometries, which are unavailable to purely organic small molecules. This feature can allow metal complexes to sample regions of chemical space within biomolecules that cannot be accessed by organic compounds. Additionally, metal complexes can perform ligand exchange reactions with biological molecules, forming covalent adducts that can perturb cellular function. Importantly, the lability of metal-ligand bonds can be tuned by the choice of metal ion, its oxidation state, and auxiliary ligands. Finally, metal complexes can coordinate ligands that are themselves biologically active, leading to dual function or even synergistic effects between the metal ion and the ligand.
The most famous examples of metal-based drugs are the platinum anticancer compounds [16] , such as cisplatin and its analogues, which have been approved for the treatment a number of human cancers. The archetypical platinum drugs target DNA via covalent interactions, forming DNA cross-links that trigger cellular apoptosis. However, this relatively non-specific mode of action can lead to side effects due to damage to normal cells; furthermore, resistance to platinum drugs can often be developed. This has stimulated the development of other types of metal complexes that act via alternative modes of action, in order to both reduce adverse effects as well as to bypass existing mechanisms of anticancer drug resistance.
Epigenetic modulation refers to changes in chromatin structure that affect how genes are expressed, but are independent of DNA sequence. In recent years, the discovery that epigenetic dysfunction may be implicated in the pathogenesis of various human diseases has opened up new avenues for potential therapeutic intervention. However, only a few examples of metal complexes targeting epigenetic marks or pathways have been reported. In this review, we A c c e p t e d M a n u s c r i p t 5 highlight recent examples of epigenetic modulation by metal complexes to illustrate the potential that inorganic compounds can have in this area. This is an emerging discipline, and to our knowledge, no review of this nature has yet been published in the literature. This review aims not to be exhaustive, but intends to showcase recent examples of metal complexes that can target epigenetic pathways via various mechanisms for potential therapeutic applications.
Broadly speaking, the metal complexes in this review target epigenetic pathways via three distinct mechanisms. In the first mechanism, the metal complex acts as a "chaperone" for a bioactive ligand that is subsequently released upon activation within the cell. Having released the ligand, the metal moiety itself may also possess bioactivity. In the second approach, a metal complex with labile ligands is able to form covalent adducts with DNA or proteins involved with epigenetic regulation. In the third mechanism, kinetically-inert metal complexes interact noncovalently with epigenetic targets. Broader reviews in the general area of inorganic medicinal chemistry have been recently published by the groups of Sadler [17] , Megger [18] , Sheldrick [19] , Che [20] , Gasser [21] , Hartinger [22] , Ott [23] , Barton [24] and others [25] [26] [27] .
Mechanisms of epigenetic modulation
In eukaryotes, nuclear DNA and histone proteins are intimately intertwined in a macromolecular structure known as chromatin. The basic functional module of chromatin is the nucleosome, which is structure consisting of a 147-base pair long DNA sequence wrapped around a heterooctameric histone complex. Two of each histone proteins H2A, H2B, H3, and H4
constitute an octamer. Histone proteins play a vital role in the organization and packaging of eukaryotic DNA [28] .
A c c e p t e d M a n u s c r i p t 6 The term "epigenetics" loosely describes heritable modifications to chromatin that affect gene expression without involving changes in the DNA sequence, although no consensus definition of epigenetics has been universally agreed upon [29] . Modifications to both DNA and histones are continually added (by epigenetic "writer" enzymes) and removed (by epigenetic "eraser" enzymes) in a tightly choreographed manner. The major epigenetic mechanisms are DNA methylation and hydroxymethylation, as well as various histone modifications [29] [30] [31] [32] . In differentiated mammalian cells, the principal epigenetic tag found in DNA is the covalent attachment of a methyl group to the C5 position of cytosine residues in CpG dinucleotides [33, 34] . Cytosines other than those in CpG can also be methylated in undifferentiated stem cells, and that this methylation is also crucial for gene regulation [35] . A family of DNA methyltransferase enzymes (DNMTs) are implicated in de novo DNA methylating activity and differential maintenance. DNMT1 functions in the replication complex to recognize hemimethylated DNA and to add methyl groups in the corresponding CpG site to newly formed daughter DNA strands [33, 36] .
Histone modifications include the methylation of arginine (R), the methylation, acetylation, ubiquitination and sumoylation of lysine (K), and the phosphorylation of serine (S) and threonine (T) [37] . Recent advances in the field have determined that lysine acetylation and methylation are key epigenetic modulator marks for transcriptional activation or repression [38] . Histone acetylation has been implicated in the control of chromatin condensation, DNA repair and replication [39] . Levels of acetylation are controlled by the competing activities of two enzymatic families: the histone acetyl transferases (HATs) that 'write' acetylation sites and the histone deacetylases (HDACs) that 'erase' acetylation sites. Recently, long noncoding RNAs Many diseases, including cancer, heart disease, diabetes, and mental illnesses are influenced by epigenetic mechanisms, and epigenetic therapy offers a potential way to influence those pathways directly [42] [43] [44] . A number of these so- The following sections discuss examples of metal complexes that have been reported to either target histones directly, or enzymes that modify chromatin. We intend to showcase the various mechanisms that have been exploited by researchers in the design of metal-based epigenetic modulators in order to achieve their desired biological functions.
Metal complexes targeting histones
Ruthenium complexes have emerged as promising alternatives to platinum-based drugs due to their potent activities against various cancers and favorable pharmacokinetic properties [45] . In Hartinger and co-workers ( Fig. 1 ) [46] . Interestingly, while the isolated ligands have shown gastric activity as mucosal protectants in vivo [47] , the coordination of these ligands into a metal complex led to the formation highly active anticancer compounds. The ruthenium(II) complex 1A hydrolyzed more rapidly in aqueous solution compared with osmium complex 1B, which is consistent with the osmium center's greater kinetical stability compared with ruthenium. Once hydrolyzed, both complexes were stable over pH 1.74-11.62. Notably, their stability to hydrochloric acid suggested that they could withstand the acidic milieu of the stomach.
Crystallographic studies of complexes 1A, 3A, 1B, and 3B with the nucleosome core particle However, 8 reacted three times faster than 7 and formed 71% of adducts with DNA, whereas 7
formed 85% adducts with histone proteins.
A nuclease digestion DNA footprinting assay with both naked DNA and NCPs revealed that 8 selectively formed adducts with guanine nucleotides with a preference for GG sites, suggesting that electrostatic attraction might be a contributing factor for reactivity, as observed for simple metal hydrates. On the other hand, the weak binding of 7 to DNA prevented the identification of strong footprints except at the termini and a single site at SuperHelix Location (SHL) ±1.5. Xray crystallography analysis of NCP-7 complexes revealed that 7 adducted to the NCP at three sites, involving bivalent coordination to glutamate, histidine and lysine side chains of the histone proteins. Treatment of NCP crystals with 8 also resulted in adduct formation at two different histone sites. The first site (histone glutamate) is also common to 7, but the second involved adducts with DNA. Hybrid quantum mechanical/molecular mechanical (QM/MM) calculations indicated that bulky phosphaadamantane ligand of 7 was a key factor that determined the histone/DNA site selectivity preference between the two complexes.
Interestingly, the apoptosis and cell cycle profiles between cells treated cisplatin, 7 or 8 were markedly distinct, as demonstrated by a multivariate analysis method. Surviving cells recover more rapidly after treatment with 7 or 8 compared with cisplatin. 8 was more toxic towards Additionally, the ability of 7 and 8 to recognize both chemical and structural features of nucleosomes could potentially allow them to target epigenetic weak points of cancer cells. anticancer activity against colorectal tumor cells both in vitro and in vivo [50] . The mechanism of action of KP1019 has been linked with DNA damage, induction of cell cycle delay, and M a n u s c r i p t 12 apoptosis [51, 52] . However, the exact molecular targets(s) of K P1019 had been unclear.
Recently, Tomar and co-workers utilized Saccharomyces cerevisiae as a model organism to elucidate the molecular target of KP1019 [53] . K P1019 was revealed to eject histones from nucleosomal DNA and interact with histone H3, but without affecting acetylated H4K8 in vitro.
Furthermore, various histone H3 mutants, particularly histone tail mutants, showed enhanced sensitivity to the antiproliferative activities of KP1019. As histone tails play an important role in maintaining nucleosome structure, these results suggest that KP1019 exerts its effect by further destroying nucleosome structure in these mutants. In normal cells, H3K56 is acetylated during DNA damage repair [54] . The markedly increased sensitivity of the H3K56A mutant to KP1019
suggests that this drug causes DNA damage, consistent with previous reports. This study is significant because it provides a possible epigenetic mechanism by which the well-known anticancer drug KP1019 can exert its antiproliferative effects. compounds have lower toxicity but can be reduced intracellularly to platinum(II) to recover their cytotoxicity [56] [57] [58] . The kinetic inertness of the Pt(IV) center allows those complexes to bypass many of the problems associated with cisplatin and its analogues [59] . Furthermore, carboxylate ligands can be easily incorporated into the octahedral Pt(IV) scaffold to further modulate the lipophilicity, stability, redox behavior, and biological activity of the prodrugs [60] .
Satraplatin, an analogue of cisplatin that contains two acetate ligands in the axial positions, has entered Phase III clinical trials for the treatment of the patients with hormone refractory prostate cancer (HRPC) [61] .
Valproic acid (VA), a commonly-used antiepileptic and anticonvulsant drug in the clinic, has recently been identified as one of the short-chain fatty acid class of HDAC inhibitors [62, 63] .
Similar with other HDAC inhibitors, VA exerts its anticancer effects in the control of biological processes in cell cycle arrest, cell apoptosis, metastasis, angiogenesis, differentiation, and senescence [64, 65] . Based on the structure of satraplatin, Tang, Shen and co-workers proposed in 2012 that VA could be used as ligand of a Pt(IV) complex to form a satraplatin-like Pt(IV)−VA (VAAP, complex 10) prodrug (Fig. 4) [66] . In the design of this complex, VA are used as axial ligands, trans to one another, so that these ligands are released upon reduction to Pt(II). VAAP was synthesized by the reaction of cis,cis,trans-diaminedichlorodihydroxy-platinum(IV)
[Pt(NH 3 ) 2 Cl 2 (OH) 2 , ACHP] with VA. A HDAC inhibition activity assay revealed that the inhibition M a n u s c r i p t cell lines (IC 50 = 0.14 µM). Importantly, the potency of VAAP was superior to ACHP, VA or a mixture of ACHP and VA, indicating that the combination of the Pt(IV) complex with the VA ligands was essential for enhanced cytotoxicity. Notably, VAAP was even more potent compared with cisplatin. Cellular distribution studies suggested that VAAP could efficiently bind to a cell membrane owing to its hydrophobicity, and then further enter into the cytosol. In the nucleus, the increase of histone acetylation by VA could loosen histone−DNA interactions, allowing the binding of the Pt(II) complex to DNA. Therefore, the synergy of the Pt(II) complex and VA could explain VAAP's high cytotoxicity. In vivo, VAAP significantly inhibited tumor growth in an A549 tumor xenograft model as compared with ACHP, and also caused no effects on mice body weights and nephrotoxicity, in contrast to ACHP. This study illustrates an important advantage of metal complexes, in that bioactive ligands can be easily attached to the metal scaffold, leading to the possibility of additive or even synergistic effects in the cell. One aspect of this study was that a direct comparison between the cytotoxicity of VAAP and a mixture of VAAP's reduction products, i.e. cisplatin and VA, was not performed, so the actual extent of synergism contained within the molecule seems to be unclear. Additionally, there was M a n u s c r i p t 15 no direct evidence in the study that showed that VAAP was reduced in the intracellular environment. The fact that VAAP showed significantly less HDAC inhibitory activity in nuclear extracts compared to AA-pretreated VAAP suggests that the crucial reduction process may represent rate-limiting step in the activation of this compound in cells.
Pt OH HO
Cl Cl SAHA is a HDAC inhibitor approved for clinical use by FDA to treat numbers of hematological and solid tumors [67, 68] . Crystal structures of human HDACs with SAHA bound show that the hydroxamic acid moiety coordinates with the active-site zinc ion [69] . Several HDAC inhibitors (HDACis) have thus been designed that are comprised of a metal-binding group, a linker domain that occupies a narrow channel and a cap group which interacts with residues on the enzyme surface.
In 2009, Marmion and co-workers attached a malonic acid (mal)-derivatized SAHA analogue, malSAHA, to a Pt(II) complex (Fig. 5) [70] .
Later, Spencer and co-workers designed a novel iron-based SAHA derivative to study the impact of a nonplanar-phenyl bioisostere, the ferrocene unit, on HDAC inhibitory activity ( However, these compounds were less toxic to MCF7 breast cancer cells than SAHA, which was attributed to their lower cellular permeability as a result of the ferrocene group. Interestingly, flow cytometry experiments revealed that 14 and 15 promoted both bulk chromatin acetylation (the endogenous substrate of class I HDACs) and the acetylation of α-tubulin (a substrate of M a n u s c r i p t 18 HDAC6) with comparable potency to SAHA. This study illustrates that modification of the aryl "cap" of SAHA can be achieved without greatly affecting its HDAC inhibitory activity. Bromodomains (BRDs) are protein-interaction modules that recruit chromatin-modifying enzymes to specific sites by recognizing acetylated lysine residues on histone tails [80] [81] [82] . In order words, BRDs act as epigenetic 'reader' modules [83] . BRD4, as a member of the bromodomain and extra-terminal domain (BET) family, regulates transcription in postmitotic cells by recruiting the positive transcription elongation factor (P-TEFb) to target promoters in response to extracellular signals [84] . Recently, BRD4 has become a potential target for epigenetic therapy because of its roles on cell cycle progression and sustaining the proliferation of tumor cells [85] . Recently, our group has discovered the first iridium(III)-based, irreversible 
JMJD2
Lysine methylation has substantial roles in chromatin dynamics [87] . Changes in the regulation of histone lysine methylation have been linked to the dysregulation of histone lysine methyltransferases or demethylases [88, 89] . JMJD (Jumonji C domain-containing) proteins, the second family of histone demethylases requiring Fe 
Conclusion
While many new compounds are highly successful during in vitro and preclinical studies, half of all drug candidates that enter clinical trials fail due to problems such as poor bioavailability, low efficacy and severe side effects. In this context, coordination of a drug to a metal complex can greatly improve aqueous solubility, passive cellular uptake and absorption, or nuclear localization [92] [93] [94] . In addition, the metal complex can itself be biologically active. A number of the examples in this review have conjugated a known epigenetic-modulating drug to a metal complex scaffold, which acts as a chaperone. For example, Tang, Shen and co-workers have incorporated VA, a HDAC inhibitor, into a Pt(IV) scaffold [66] . The reduction of the Pt(IV)
prodrug VAAP inside the cell releases both VA and the cytotoxic Pt(II) moiety, leading to A c c e p t e d M a n u s c r i p t 26 simultaneous DNA damage and the impairment of DNA repair. Notably, VAAP was more potent than both cisplatin as well as the isolated metal complex and ligands, demonstrating that the assembly of the subunits into an intact complex was critical for biological activity. A similar principle was employed by Marmion and co-workers, who grafted a SAHA analogue onto a Pt(II) diammine core [70] . Such dual-action drugs may be more effective than the original parent drug(s), and may also be able to circumvent existing drug resistance mechanisms and/or achieve greater selectivity for cancer cells over normal cells. However, one drawback of the hybrid approach is that the attachment of bioactive ligands to metal scaffolds makes it more difficult to modulate the toxicity of the components, as it would be possible for combination therapies. Moreover, synthetic difficulties may restrict the types of ligands and metal scaffolds that can be conjugated together to form hybrid compounds.
Besides drug-metal complex conjugates, other metal complexes appear to directly target protein via either covalent or non-covalent modes of action. For example, RAPTA-C, a promising antimetastasis compound whose precise mechanism of action has not yet been fully elucidated, was recently shown by Davey and co-workers to bind to histone proteins at three different sites [48] . Notably, that study also showcased the fact that selectivity of a particular metal complex class for molecular targets (e.g. histones or DNA) can be switched simply by replacement of one ligand for another. The iridium(III) solvato complexes developed by our group also selectively and covalently interact with BRD4 in order to exert their epigenetic modulatory effects [86] .
Kinetically-inert metal complexes, such as the JMJD2-inihbiting iridium(III) compound developed by our group, represent another means of inhibitor epigenetic modifying enzymes M a n u s c r i p t 27 [91] . A summary of the targets and mechanisms of the inorganic epigenetic modulators highlighted in this review is presented in Table 1 .
Towards the future, we envision that as biochemical and cellular investigations into epigenetic regulation continue to progress, additional epigenetic molecular targets may be unveiled that could potentially be targeted by metal complexes. Indeed, we have highlighted recent mechanistic investigations into existing metal-containing drug candidates, such as RAED-C, RAPTA-C and KP-1019 that reveal that those compounds may be targeting epigenetic proteins in order to exert their antiproliferative activity. However, despite the promising preliminary studies that we have described here, more work needs to be done in order to further progress the field of inorganic epigenetic modulators. One key issue that has to be addressed is selectivity. Given that many of these complexes interact with biomolecules covalently, the unwanted binding of metal complexes to cellular machinery should be avoided as much as possible. Possible strategies include the prodrug approach discussed above, where Pt(IV) species are reduced to bioactive Pt(II) within the cell, or perhaps a photoactivatable release mechanism such as the SubH-linked Pt(II) complex described by Kasparkova and co-workers. An alternative mechanism for achieving selectivity may be in the use of kinetically-inert metal complexes, for which the group of Meggers has convincingly shown can display tremendous selectivity for target kinases despite using purely non-covalent interactions [18, 95, 96] .
However, only one kinetically-inert epigenetic modulator (the JMJD2-inhibiting iridium(III) complex) appears to have been reported so far. Additionally, given that the ultimate goal of these compounds is human therapy, we encourage researchers to test their candidate complexes in in vivo animal models to ascertain whether or not the in vitro activities of the A c c e p t e d M a n u s c r i p t 28 compounds can be reproduced in a more complicated system. Finally, although no metal-based compound developed a priori as an epigenetic modulator has yet been approved for clinical use, we note that some metal-based compounds that have already entered human clinical trials, such as KP1019, or are progressing towards clinical trials, such as RAPTA-C, were found to act against epigenetic targets only after their anti-cancer activities were well-known. Therefore, it may well be possible that existing metal-based compounds in clinical use may actually also target epigenetic regulation as a potential mechanism of action. Given the promising studies that have been reported in the last few years, we are hopeful that it is only a matter of time before the first metal-based epidrug will be approved for clinical use. 
